|
|
Article: Bionomics licenses epilepsy test.
- Article from:
- BIOTECH Patent News
- Article date:
- September 1, 2004
CopyrightCOPYRIGHT 2004 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Bionomics Limited (Adelaide, Australia) granted a licence to Boston-based Athena Diagnostics (Boston, MA) to market Bionomics' childhood epilepsy diagnostic to neurologists in North America and Japan.
Athena, specialists in diagnostic testing for neurological disorders, plans to make the gene-based Severe Myoclonic Epilepsy of Infancy (SMEI) test available later this calendar year to over 5,000 neurologists for whom it currently performs diagnostic tests.
Until now there has been no genetic test available to clinicians to allow them to distinguish SMEI from less serious forms of epilepsy. Early diagnosis should reduce the cost associated with current ...